Bionano Genomics Q2 revenue rises on increased clinical adoption

Bionano Genomics

10/08/2026 21:24

Overview
Genome analysis solutions provider's Q2 revenue rose 21% yr/yr to $8.2 mln
Gross margin for Q2 improved to 53% from 52% a year earlier
Company retired all outstanding secured convertible debentures, eliminating secured debt obligations

Outlook
Bionano sees Q3 2026 revenue between $8.2 mln and $8.6 mln
Company expects full-year 2026 revenue of $31 mln to $33 mln
Growth expected to be driven by increased clinical adoption and utilization at clinical sites

Result Drivers
CLINICAL ADOPTION - Co said growth in consumable sales was primarily driven by increased clinical adoption and greater utilization at existing and new clinical sites
EXPANDING EVIDENCE BASE - Co cited a year-over-year increase in OGM studies presented at major genetics conferences as supporting broader adoption

Company press release: ID:nGNX3RLKsl

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$8.20 mln
$7.48 mln (2 Analysts)
Q2 Gross Margin
 
53.00%
 
Q2 Adjusted Operating Expenses
 
$8.70 mln
 
Q2 Operating Expenses
 
$11.53 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Bionano Genomics, Inc. is $5.00, about 331% above its August 7 closing price of $1.16

Reuters Recommended Reads
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - Tenax heart drug fails to improve walking results in study, shares plunge

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)